Lomustine
Top View
- CNBEV Protocol
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- Clinically Relevant Concentrations of Anticancer Drugs: a Guide for Nonclinical Studies Dane R
- DRUG NAME: Lomustine
- Ceenu Product Monograph
- Therapeutic Options in Recurrent Glioblastoma – an Update Katharina
- Medications That Are Immunosuppressive Or Immunomodulatory (This List Is Not All-Inclusive)
- Emetogenic Potential of Antineoplastic Agents
- Fluorescence-Guided High-Grade Glioma Surgery More Than Four Hours After 5-Aminolevulinic Acid Administration
- Recurrent Glioblastoma: from Molecular Landscape to New Treatment Perspectives
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- High-Dose Methotrexate-Based Immuno-Chemotherapy for Elderly Primary CNS Lymphoma Patients (PRIMAIN Study)
- Combination of ALA-Induced Fluorescence-Guided Resection And
- Salvage Chemotherapy for Oligodendroglioma
- Enhanced Anticancer Properties of Lomustine in Conjunction with Docosahexaenoic Acid in Glioblastoma Cell Lines
- BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
- Clinical Challenges in Caring for Patients with Diabetes and Cancer